Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10716737 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Persad S, et al. (2000) Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A 97, 3207-12 10716737
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum no change compared to control
serum ILK (human) no change compared to control WT
serum ILK (human) no change compared to control KD
serum PTEN (human) decrease
KP-392 no change compared to control

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum PTEN (human) decrease
serum ILK (human) no change compared to control wild-type (WT)
serum serum ILK (human) decrease kinase-deficient mutant of ILK (KD)
KP-392 decrease
fibronectin increase cells plated on fibronectin
fibronectin fibronectin ILK (human) no effect upon treatment-induced increase WT
fibronectin fibronectin ILK (human) no effect upon treatment-induced increase KD
serum fibronectin PTEN (human) no effect upon treatment-induced increase WT
polyHEMA increase cells in suspension
polyHEMA ILK (human) no effect upon treatment-induced increase WT
polyHEMA ILK (human) inhibit treatment-induced increase KD inhibits
polyHEMA PTEN (human) inhibit treatment-induced increase WT

S21-p - GSK3A (human)
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum serum ILK (human) no effect upon treatment-induced increase WT
serum serum ILK (human) inhibit treatment-induced increase KD
serum serum PTEN (human) inhibit treatment-induced increase WT

S9-p - GSK3B (human)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum serum ILK (human) no effect upon treatment-induced increase WT
serum serum ILK (human) inhibit treatment-induced increase KD
serum serum PTEN (human) inhibit treatment-induced increase WT


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.